[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636076":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":30,"centralContacts":35,"locations":40,"responsibleParty":67,"collaborators":10,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":10,"studyType":84,"phases":10,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":93,"whyStopped":10,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Università Vita-Salute San Raffaele","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients > 18 years and \u003C75 years with advanced heart failure",null,"1. Age \\> 18 and \\\u003C 75 years\n2. Heart failure with left ventricular ejection fraction ≤ 35%\n3. Persistent symptoms of heart failure, New York Heart Association class III or IV\n4. Requirement for high-dose diuretic therapy, specifically Furosemide \\> 50 mg\u002Fday orally as per routine clinical practice\n5. At least one of the following additional indicators of severity or refractoriness:\n\n   * need for progressive escalation of diuretics,\n   * intolerance to optimized medical therapy,\n   * persistence of symptoms despite advanced treatments such as (but not limited to) cardiac resynchronization therapy (CRT-D)and\u002For MitraClip\n6. Ability and willingness to provide written informed consent for participation and for the processing of clinical data for research purposes",[13,14],"Drug: GDMT","Other: Quality of life questionnaire",[16,26],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","GDMT","Percentage of patients receiving GDMT in advanced heart failure",[9],[22,23,24,25],"beta-blocker","mineralcorticoid receptor antagonist","SGLT2 inhibitor","renin-angiotensin-aldosterone system drug",{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"Quality of life questionnaire","Absoute Quality of life questionnaire scores (SF 36 questionnaire and EqVAS scale, both validated in Italian language",[9],[31],{"name":32,"affiliation":33,"role":34},"Anna Maria Scandroglio, MD","IRCCS Ospedale San Raffaele","PRINCIPAL_INVESTIGATOR",[36],{"name":32,"role":37,"phone":38,"phoneExt":10,"email":39},"CONTACT","0226437154 \u002F +393473249312","scandroglio.mara@hsr.it",[41,56],{"facility":42,"status":10,"city":43,"state":10,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"ASST Ospedale Papa Giovanni XXIII","Bergamo","24127","Italy","IT",{"type":48,"coordinates":49},"Point",[50,51],9.66721,45.69601,{"lat":51,"lon":50},[54],{"name":55,"role":37,"phone":10,"phoneExt":10,"email":10},"Attilio Iacovoni, MD",{"facility":33,"status":10,"city":57,"state":10,"zip":58,"country":45,"countryCode":46,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Milan","20132",{"type":48,"coordinates":60},[61,62],9.18951,45.46427,{"lat":62,"lon":61},[65],{"name":32,"role":37,"phone":66,"phoneExt":10,"email":39},"02.26437154 \u002F +393473249312",{"type":34,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Marina Pieri","MD","100636076","evaluating-adherence-to-guideline-directed-medical-therapy-in-patients-with-advanced-heart-failure-100636076",false,"NCT07560982","Evaluating Adherence to Guideline-Directed Medical Therapy in Patients With Advanced Heart Failure","Evaluating Adherence to Guideline- Directed Medical Therapy Using the Four-Pillar Strategy in Patients With Advanced Heart Failure: the Advanced Heart Failure Unified Board (Ad-HUB) Study","ad-HUB","Inclusion Criteria:\n\n1. Age \\> 18 and \\\u003C 75 years\n2. Heart failure with left ventricular ejection fraction ≤ 35%\n3. Persistent symptoms of heart failure, New York Heart Association class III or IV\n4. Requirement for high-dose diuretic therapy, specifically Furosemide \\> 50 mg\u002Fday orally as per routine clinical practice\n5. At least one of the following additional indicators of severity or refractoriness:\n6. need for progressive escalation of diuretics,\n7. intolerance to optimized medical therapy,\n8. persistence of symptoms despite advanced treatments such as (but not limited to) cardiac resynchronization therapy (CRT-D)and\u002For MitraClip\n9. Ability and willingness to provide written informed consent for participation and for the processing of clinical data for research purposes\n\nExclusion Criteria:\n\n1. Age ≤ 18 years or ≥ 75 years\n2. Left ventricular ejection fraction \\> 35%\n3. Mild or absent symptoms (New York Heart Association class I-II)\n4. Good response to optimized conventional guideline-directed medical therapy\n5. Extreme frailty or severe non-reversible disability, or psychiatric or cognitive disorders preventing adherence to follow-up\n6. Pregnant or breastfeeding women","ALL","18 Years","75 Years",{"count":82,"type":83},300,"ESTIMATED","OBSERVATIONAL","A Prospective Observational, Multi-Center, Real-World Pharmacological Study Evaluating Adherence to Guideline-Directed Medical Therapy Using the Four-Pillar Strategy in Patients with Advanced Heart Failure",[87],"Heart Failure",[89,90,91,92],"Medical therapy","Quality of life","Heart failure","mechanical circulatory support","NOT_YET_RECRUITING","2026-05-04",{"date":96,"type":97},"2026-05-08","ACTUAL",{"date":99,"type":83},"2026-07-01",{"date":101,"type":83},"2036-07-01",{"name":5,"class":6},2]